Oncoinvent ASA (0RU5) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to this second half year 2025 presentation of Onko Invent. My name is Øystein Saug. I'm the CEO of the company. And in a few minutes, we will give you an overview of the highlights and the financials for the period. But before we do, and particularly for those of you who are new to the story and those of you who need a refresher, I will give you a short introduction to the technology at the beginning. You can ask questions as we go along that we will try to answer at the end of the session. And you will see on your screens that there's a button for asking questions. So if you have questions, press on that button. This is the disclaimer for those of you who are interested in that. And going to the introduction, the problem that we are aiming to solve in this company is cancer that has spread to the peritoneum or to the abdominal cavity, as it's also known. This is not really an indication per se, but it is a stage of disease that you will see in many different types of cancer. It is resulting from ovarian cancer, colorectal cancer, or various types of stomach cancers. And it is a disease where there are, or this disease is something where you don't really have good treatment options for the patients today. In many other cancers, you will have immunotherapies or other modern medicines that really solve the problem for the patients, but this is not the case for peritoneal carcinomatosis. What these patients will get is surgery and surgery works to a certain extent. It will add maybe one to two years to the life expectancy of the patient. So it's a good thing and most patients will get it. But no matter how good the surgery, there will be micrometastases left in the peritoneum in the abdominal cavity that will cause the cancer to return. And...